Efficacy and tolerability of a cocktail of bacteriophages
Pseudomonas aeruginosa (PhagoBurn): a randomised, c
trial

Lancet Infectious Diseases, The

19, 35-45

DOI: 10.1016/s1473-3099(18)30482-1

Citation Report

#	Article	IF	Citations
1	Antibiotic Therapy Using Phage Depolymerases: Robustness Across a Range of Conditions. Viruses, 2018, 10, 622.	1.5	37
2	A Wake-Up Call: We Need Phage Therapy Now. Viruses, 2018, 10, 688.	1.5	104
3	Salvage Debridement, Antibiotics and Implant Retention (â€œDAIRâ€) With Local Injection of a Selected Cocktail of Bacteriophages: Is It an Option for an Elderly Patient With Relapsing Staphylococcus aureus Prosthetic-Joint Infection?. Open Forum Infectious Diseases, 2018, 5, ofy269.	0.4	83
6	Bacteriophages in Natural and Artificial Environments. Pathogens, 2019, 8, 100.	1.2	124
7	Hurdles for Phage Therapy to Become a Realityâ€”An Editorial Comment. Viruses, 2019, 11, 557.	1.5	24
8	Factors determining phage stability/activity: challenges in practical phage application. Expert Review of Anti-Infective Therapy, 2019, 17, 583-606.	2.0	82
9	Human Virome and Disease: High-Throughput Sequencing for Virus Discovery, Identification of Phage-Bacteria Dysbiosis and Development of Therapeutic Approaches with Emphasis on the Human Gut. Viruses, 2019, 11, 656.	1.5	111
10	Phage therapy administered noninvasively could be effective in thin tubes subject to episodic flow despite washout: a simulation study. Physical Biology, 2019, 16, 054001.	0.8	3
11	Bacteriophages Improve Outcomes in Experimental Staphylococcus aureus Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1126-1133.	2.5	54
13	Phage Therapy: A Practical Approach. , 2019, , .		22
14	Bacterial Resistance to Phage and Its Impact on Clinical Therapy. , 2019, , 59-88.		12
15	Whatâ€™s Old Is New Again: Bacteriophage Therapy in the 21st Century. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	16
16	Recoding the metagenome: microbiome engineering in situ. Current Opinion in Microbiology, 2019, 50, 28-34.	2.3	12
17	Quorum Quenching Lactonase Strengthens Bacteriophage and Antibiotic Arsenal Against Pseudomonas aeruginosa Clinical Isolates. Frontiers in Microbiology, 2019, 10, 2049.	1.5	41
18	Emerging therapies against infections with Pseudomonas aeruginosa. F1000Research, 2019, 8, 1371.	0.8	64
19	Turning the Phage on Treatment of Antimicrobial-Resistant Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1081-1082.	2.5	13
20	Bacteriophages as Alternatives to Antibiotics in Clinical Care. Antibiotics, 2019, 8, 138.	1.5	122
21	Phage Therapy with a focus on the Human Microbiota. Antibiotics, 2019, 8, 131.	1.5	83

#	Article	IF	Citations
22	Development of a qPCR platform for quantification of the five bacteriophages within bacteriophage cocktail 2 (BFC2). Scientific Reports, 2019, 9, 13893.	1.6	19
23	Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol. Viruses, 2019, 11, 891.	1.5	98
24	Hostâ€“Pathogen Interactions. Clinical Therapeutics, 2019, 41, 1899-1901.	1.1	0
25	Robust Approaches for the Production of Active Ingredient and Drug Product for Human Phage Therapy. Frontiers in Microbiology, 2019, 10, 2289.	1.5	29
26	The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole. Viruses, 2019, 11, 96.	1.5	113
27	Perspectives of Phage Therapy in Non-bacterial Infections. Frontiers in Microbiology, 2018, 9, 3306.	1.5	49
29	Phage therapyâ€™s latest makeover. Nature Biotechnology, 2019, 37, 581-586.	9.4	65
30	Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights. Expert Review of Clinical Pharmacology, 2019, 12, 635-642.	1.3	30
31	Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections. Frontiers in Pharmacology, 2019, 10, 513.	1.6	261
32	Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory. Journal of Clinical Microbiology, 2019, 57, .	1.8	15
33	Specific and Selective Bacteriophages in the Fight against Multidrug-resistant Acinetobacter baumannii. Virologica Sinica, 2019, 34, 347-357.	1.2	22
34	Phage Therapy Regulation: From Night to Dawn. Viruses, 2019, 11, 352.	1.5	89
35	Recent Advances in Non-Conventional Antimicrobial Approaches for Chronic Wound Biofilms: Have We Found the â€˜Chink in the Armorâ€™?. Biomedicines, 2019, 7, 35.	1.4	52
36	Current State of Compassionate Phage Therapy. Viruses, 2019, 11, 343.	1.5	144
37	Determinants of Phage Host Range in Staphylococcus Species. Applied and Environmental Microbiology, 2019, 85, .	1.4	59
38	Phage-Derived Antibacterials: Harnessing the Simplicity, Plasticity, and Diversity of Phages. Viruses, 2019, 11, 268.	1.5	50
39	Towards Inhaled Phage Therapy in Western Europe. Viruses, 2019, 11, 295.	1.5	33
40	The PlyB Endolysin of Bacteriophage vB_BanS_Bcp1 Exhibits Broad-Spectrum Bactericidal Activity against Bacillus cereus Sensu Lato Isolates. Applied and Environmental Microbiology, 2019, 85, .	1.4	22

#	Article	IF	Citations
41	Successful Treatment of Antibiotic-resistant, Poly-microbial Bone Infection With Bacteriophages and Antibiotics Combination. Clinical Infectious Diseases, 2019, 69, 2015-2018.	2.9	151
42	Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review. Frontiers in Microbiology, 2019, 10, 539.	1.5	922
43	Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Cell Host and Microbe, 2019, 25, 219-232.	5.1	657
44	Clinical application of bacteriophages in Europe. Microbiology Australia, 2019, 40, 8.	0.1	16
45	Bacteriophage therapy: coping with the growing antibiotic resistance problem. Microbiology Australia, 2019, 40, 5.	0.1	9
46	Pharmacological limitations of phage therapy. Upsala Journal of Medical Sciences, 2019, 124, 218-227.	0.4	62
47	Exploring the whole standard operating procedure for phage therapy in clinical practice. Journal of Translational Medicine, 2019, 17, 373.	1.8	23
48	Biological challenges of phage therapy and proposed solutions: a literature review. Expert Review of Anti-Infective Therapy, 2019, 17, 1011-1041.	2.0	50
49	Phages amid antimicrobial resistance. Critical Reviews in Microbiology, 2019, 45, 701-711.	2.7	20
50	Promises and Pitfalls of In Vivo Evolution to Improve Phage Therapy. Viruses, 2019, 11, 1083.	1.5	24
51	Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections. Viruses, 2019, 11, 18.	1.5	90
52	Phage Therapy in the Postantibiotic Era. Clinical Microbiology Reviews, 2019, 32, .	5.7	505
53	Phage therapy: Current status and perspectives. Medicinal Research Reviews, 2020, 40, 459-463.	5.0	102
54	Frontiers in Molecular Evolutionary Medicine. Journal of Molecular Evolution, 2020, 88, 3-11.	0.8	18
55	Review article: bacteriophages in gastroenterologyâ€"from biology to clinical applications. Alimentary Pharmacology and Therapeutics, 2020, 51, 53-63.	1.9	31
56	Phage therapy for severe bacterial infections: a narrative review. Medical Journal of Australia, 2020, 212, 279-285.	0.8	37
57	Current landscape in the discovery of novel antibacterial agents. Clinical Microbiology and Infection, 2020, 26, 596-603.	2.8	85
58	Bacteriophage Therapeutics: A Primer for Clinicians on Phageâ€Antibiotic Combinations. Pharmacotherapy, 2020, 40, 153-168.	1.2	56

#	Article	IF	Citations
59	Therapeutic bacteriophages as a rescue treatment for drugâ€resistant infections â€“ anin vivostudies overview. Journal of Applied Microbiology, 2020, 128, 985-1002.	1.4	35
60	Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections. Advanced Science, 2020, 7, 1901872.	5.6	173
61	Harnessing the microbiota for therapeutic purposes. American Journal of Transplantation, 2020, 20, 1482-1488.	2.6	14
62	Application of Bacteriophages in Nanotechnology. Nanomaterials, 2020, 10, 1944.	1.9	34
63	Tackling Multidrug Resistance in Streptococci â€“ From Novel Biotherapeutic Strategies to Nanomedicines. Frontiers in Microbiology, 2020, 11, 579916.	1.5	24
64	Transcriptomic Analysis Reveals the Dependency of Pseudomonas aeruginosa Genes for Double-Stranded RNA Bacteriophage phiYY Infection Cycle. IScience, 2020, 23, 101437.	1.9	9
65	Phages Needed against Resistant Bacteria. Viruses, 2020, 12, 743.	1.5	2
66	Kinetic Fingerprinting Links Bacteria-Phage Interactions with Emergent Dynamics: Rapid Depletion of Klebsiella pneumoniae Indicates Phage Synergy. Antibiotics, 2020, 9, 408.	1.5	4
67	Emerging Strategies to Combat Î²-Lactamase Producing ESKAPE Pathogens. International Journal of Molecular Sciences, 2020, 21, 8527.	1.8	22
68	Phage Therapy: Towards a Successful Clinical Trial. Antibiotics, 2020, 9, 827.	1.5	59
69	Bacteriophages as Therapeutic Preparations: What Restricts Their Application in Medicine. Biochemistry (Moscow), 2020, 85, 1350-1361.	0.7	12
70	Bacteriophage Therapy for Clinical Biofilm Infections: Parameters That Influence Treatment Protocols and Current Treatment Approaches. Antibiotics, 2020, 9, 799.	1.5	23
71	Health Impact and Therapeutic Manipulation of the Gut Microbiome. High-Throughput, 2020, 9, 17.	4.4	14
72	Standardized bacteriophage purification for personalized phage therapy. Nature Protocols, 2020, 15, 2867-2890.	5.5	109
73	Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections. Frontiers in Microbiology, 2020, 11, 1509.	1.5	47
74	Phage Therapy. , 2020, , 777-787.e3.		4
75	Rethinking Phage Ecology by Rooting it Within an Established Plant Framework. Phage, 2020, 1, 121-136.	0.8	8
76	Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?. Clinical Therapeutics, 2020, 42, 1659-1680.	1.1	118

#	Article	IF	Citations
77	Complete Genome Sequences of 10 Phages Lytic against Multidrug-Resistant Pseudomonas aeruginosa. Microbiology Resource Announcements, 2020, 9, .	0.3	8
78	Isolation and Characterization of a Novel Myophage Abp9 Against Pandrug Resistant Acinetobacter baumannii. Frontiers in Microbiology, 2020, 11, 506068.	1.5	18
79	Local Bacteriophage Delivery for Treatment and Prevention of Bacterial Infections. Frontiers in Microbiology, 2020, 11, 538060.	1.5	36
80	Optimizing bacteriophage engineering through an accelerated evolution platform. Scientific Reports, 2020, 10, 13981.	1.6	26
81	The Rationale for Using Bacteriophage to Treat and Prevent Periprosthetic Joint Infections. Frontiers in Microbiology, 2020, 11, 591021.	1.5	9
82	Phage Therapy: Primer and Role in the Treatment of MDROs. Current Infectious Disease Reports, 2020, 22, 1.	1.3	6
83	Editorial: Manufacturing, Formulation and Delivery Issues for Phage Therapy to Become A Reality. Frontiers in Microbiology, 2020, 11, 584137.	1.5	4
84	The Safety and Efficacy of Phage Therapy for Superficial Bacterial Infections: A Systematic Review. Antibiotics, 2020, 9, 754.	1.5	32
85	Clinical utilization of bacteriophages: a new perspective to combat the antimicrobial resistance in Brazil. Brazilian Journal of Infectious Diseases, 2020, 24, 239-246.	0.3	6
86	Current challenges and future opportunities of phage therapy. FEMS Microbiology Reviews, 2020, 44, 684-700.	3.9	151
87	New strategies and targets for antibacterial discovery. , 2020, , 249-272.		2
88	Pharmacokinetics/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study. Clinical Microbiology and Infection, 2020, 26, 1229-1235.	2.8	33
89	The Israeli Phage Bank (IPB). Antibiotics, 2020, 9, 269.	1.5	32
90	Polyvalent Phage CoNShP-3 as a Natural Antimicrobial Agent Showing Lytic and Antibiofilm Activities against Antibiotic-Resistant Coagulase-Negative Staphylococci Strains. Foods, 2020, 9, 673.	1.9	18
91	Animal Models to Translate Phage Therapy to Human Medicine. International Journal of Molecular Sciences, 2020, 21, 3715.	1.8	30
92	Bacteriophages, a New Therapeutic Solution for Inhibiting Multidrug-Resistant Bacteria Causing Wound Infection: Lesson from Animal Models and Clinical Trials . Drug Design, Development and Therapy, 2020, Volume 14, 1867-1883.	2.0	54
93	Optimizing the Timing and Composition of Therapeutic Phage Cocktails: A Control-Theoretic Approach. Bulletin of Mathematical Biology, 2020, 82, 75.	0.9	13
94	PHAGE Futures Congress Meeting Summary Washington, DC January 29 to 30, 2020. Phage, 2020, 1, 83-86.	0.8	0

#	Article	IF	Citations
95	Biocompatible In Situ Polymerization of Multipurpose Polyacrylamide-Based Hydrogels on Skin via Silver Ion Catalyzation. ACS Applied Materials & Interfaces, 2020, 12, 31079-31089.	4.0	36
96	Bacteriophage-mediated manipulation of the gut microbiome â€“ promises and presents limitations. FEMS Microbiology Reviews, 2020, 44, 507-521.	3.9	65
97	Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?. Frontiers in Microbiology, 2020, 11, 1434.	1.5	71
98	Interactions between Bacteriophages and Eukaryotic Cells. Scientifica, 2020, 2020, 1-8.	0.6	15
99	Good Manufacturing Practice (GMP) Compliance for Phage Therapy Medicinal Products. Frontiers in Microbiology, 2020, 11, 1161.	1.5	40
100	Phage Therapy in the Year 2035. Frontiers in Microbiology, 2020, 11, 1171.	1.5	58
101	Growing Trend of Fighting Infections in Aquaculture Environmentâ€"Opportunities and Challenges of Phage Therapy. Antibiotics, 2020, 9, 301.	1.5	35
102	Isolation of a Novel Jumbo Bacteriophage Effective Against Klebsiella aerogenes. Frontiers in Medicine, 2020, 7, 67.	1.2	20
103	Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules, 2020, 25, 1340.	1.7	653
104	Development of a Bacteriophage Cocktail to Constrain the Emergence of Phage-Resistant Pseudomonas aeruginosa. Frontiers in Microbiology, 2020, 11, 327.	1.5	92
105	The forgotten tale of Brazilian phage therapy. Lancet Infectious Diseases, The, 2020, 20, e90-e101.	4.6	18
106	Immune-Microbiota Interplay and Colonization Resistance in Infection. Molecular Cell, 2020, 78, 597-613.	4.5	50
107	Topical application of bacteriophages for treatment of wound infections. Translational Research, 2020, 220, 153-166.	2.2	50
108	Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae. Emerging Microbes and Infections, 2020, 9, 771-774.	3.0	99
109	Bacteriophage Therapy: Developments and Directions. Antibiotics, 2020, 9, 135.	1.5	74
110	Targeting Plasmids to Limit Acquisition and Transmission of Antimicrobial Resistance. Frontiers in Microbiology, 2020, 11, 761.	1.5	83
111	Combining bacteriophages and dalbavancin for salvage therapy of complex Staphylococcus aureus extradural empyema. MÃ©decine Et Maladies Infectieuses, 2020, 50, 458-459.	5.1	4
112	Medical innovations to maintain the function in patients with chronic PJI for whom explantation is not desirable: a pathophysiology-, multidisciplinary-, and experience-based approach. Sicot-j, 2020, 6, 26.	0.8	9

#	Article	IF	Citations
113	A Review of Topical Phage Therapy for Chronically Infected Wounds and Preparations for a Randomized Adaptive Clinical Trial Evaluating Topical Phage Therapy in Chronically Infected Diabetic Foot Ulcers. Antibiotics, 2020, 9, 377.	1.5	38
114	Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?. Pharmaceutics, 2020, 12, 624.	2.0	20
115	Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii. Microorganisms, 2020, 8, 935.	1.6	96
116	Bacteriophages for Chronic Wound Treatment: From Traditional to Novel Delivery Systems. Viruses, 2020, 12, 235.	1.5	55
117	Phage therapy efficacy: a review of the last 10 years of preclinical studies. Critical Reviews in Microbiology, 2020, 46, 78-99.	2.7	90
118	Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections. Virus Genes, 2020, 56, 136-149.	0.7	33
119	Controlled release of silver ions from AgNPs using a hydrogel based on konjac glucomannan and chitosan for infected wounds. International Journal of Biological Macromolecules, 2020, 149, 148-157.	3.6	69
120	Therapeutic applications of lytic phages in human medicine. Microbial Pathogenesis, 2020, 142, 104048.	1.3	31
121	Carbapenem-resistant Acinetobacter baumannii in Military Burn Centre. Burns, 2020, 46, 747-748.	1.1	2
122	Using Bacteriophages as a Trojan Horse to the Killing of Dual-Species Biofilm Formed by Pseudomonas aeruginosa and Methicillin Resistant Staphylococcus aureus. Frontiers in Microbiology, 2020, 11, 695.	1.5	32
123	Alternatives to antibiotics in a One Health context and the role genomics can play in reducing antimicrobial use. Clinical Microbiology and Infection, 2020, 26, 1617-1621.	2.8	15
124	The varying effects of a range of preservatives on Myoviridae and Siphoviridae bacteriophages formulated in a semiâ€solid cream preparation. Letters in Applied Microbiology, 2020, 71, 203-209.	1.0	6
125	Application of Adaptive Evolution to Improve the Stability of Bacteriophages during Storage. Viruses, 2020, 12, 423.	1.5	25
126	Novel Therapeutics for the Treatment of Burn Infection. Surgical Infections, 2021, 22, 113-120.	0.7	6
127	Genetic manipulation of phages for therapy using BRED. Current Opinion in Biotechnology, 2021, 68, 8-14.	3.3	14
128	Anti-phage serum antibody responses and the outcome of phage therapy. Folia Microbiologica, 2021, 66, 127-131.	1.1	9
129	Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infectious Diseases, The, 2021, 21, 427-436.	4.6	170
130	Bacteriophages: it's a medicine, Jim, but not as we know it. Lancet Infectious Diseases, The, 2021, 21, 309-311.	4.6	32

#	Article	IF	Citations
131	Human Gut Microbiome: A Potential Prospective to Counter Antibiotic-Resistant Pathogens. , 2022, , 368-368.		2
132	Phage Therapy. Updates in Clinical Dermatology, 2021, , 195-201.	0.1	0
133	Bacteriophage: Therapeutics and Diagnostics Development. , 2021, , 252-258.		0
134	Selection of Disease Targets for Phage Therapy. , 2021, , 1129-1150.		0
135	Bacterial biofilms: their role in chronical infection processes and the means to combat them. Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia, 2021, 39, 14.	0.1	7
136	Nanophyto-gel against multi-drug resistant Pseudomonas aeruginosa burn wound infection. Drug Delivery, 2021, 28, 463-477.	2.5	19
137	Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier. Pharmaceuticals, 2021, 14, 34.	1.7	36
138	A Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. Viruses, 2021, 13, 60.	1.5	65
139	Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis. International Journal of Molecular Sciences, 2021, 22, 735.	1.8	20
140	Animal Models of Phage Therapy. Frontiers in Microbiology, 2021, 12, 631794.	1.5	13
141	Bacteriophage as Biocontrol Agents. , 2021, , 751-766.		0
142	Photoactive Silver Nanoagents for Backgroundless Monitoring and Precision Killing of Multidrug-Resistant Bacteria. Nanotheranostics, 2021, 5, 472-487.	2.7	8
143	Phage Therapy: The Pharmacology of Antibacterial Viruses. Current Issues in Molecular Biology, 2021, 40, 81-164.	1.0	40
144	Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts. Archives of Microbiology, 2021, 203, 1271-1279.	1.0	19
145	HSF1 Alleviates Microthrombosis and Multiple Organ Dysfunction in Mice with Sepsis by Upregulating the Transcription of Tissue-Type Plasminogen Activator. Thrombosis and Haemostasis, 2021, 121, 1066-1078.	1.8	2
146	Overcoming Challenges to Make Bacteriophage Therapy Standard Clinical Treatment Practice for Cystic Fibrosis. Frontiers in Microbiology, 2020, 11, 593988.	1.5	13
147	Potential of Therapeutic Bacteriophages in Nosocomial Infection Management. Frontiers in Microbiology, 2021, 12, 638094.	1.5	11
149	Multi-Drugâ€“Resistant Organisms in Burn Infections. Surgical Infections, 2021, 22, 103-112.	0.7	13

#	Article	IF	Citations
150	Targeting of Mammalian Glycans Enhances Phage Predation in the Gastrointestinal Tract. MBio, 2021, 12, .	1.8	36
151	Pseudomonas aeruginosa Resistance to Bacteriophages and Its Prevention by Strategic Therapeutic Cocktail Formulation. Antibiotics, 2021, 10, 145.	1.5	14
152	A Phage Therapy Guide for Clinicians and Basic Scientists: Background and Highlighting Applications for Developing Countries. Frontiers in Microbiology, 2020, 11, 599906.	1.5	17
153	Improving the Inhibitory Effect of Phages against Pseudomonas aeruginosa Isolated from a Burn Patient Using a Combination of Phages and Antibiotics. Viruses, 2021, 13, 334.	1.5	25
154	Phage susceptibility testing and infectious titer determination through wide-field lensless monitoring of phage plaque growth. PLoS ONE, 2021, 16, e0248917.	1.1	10
155	Phage cocktail powder for Pseudomonas aeruginosa respiratory infections. International Journal of Pharmaceutics, 2021, 596, 120200.	2.6	27
156	The Effect of Oxygen Availability on Bacteriophage Infection: A Review. Phage, 2021, 2, 16-25.	0.8	2
157	Molecular Characterization of Ahp2, a Lytic Bacteriophage of Aeromonas hydrophila. Viruses, 2021, 13, 477.	1.5	4
158	Potential of Inhaled Bacteriophage Therapy for Bacterial Lung Infection. , 0, , .		1
159	Learning From Mistakes: The Role of Phages in Pandemics. Frontiers in Microbiology, 2021, 12, 653107.	1.5	15
160	Phage Are All the Rage: Bacteriophage in Clinical Practice. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 749-753.	0.6	2
161	Fagterapi mot antibiotikaresistente bakterier – er det enÂreell lÃ¸sning?. Naturen, 2021, 145, 27-35.	0.0	0
163	The human oral phageome. Periodontology 2000, 2021, 86, 79-96.	6.3	25
164	The clinical path to deliver encapsulated phages and lysins. FEMS Microbiology Reviews, 2021, 45, .	3.9	20
165	Progress and Pitfalls of Bacteriophage Therapy in Critical Care: A Concise Definitive Review. , 2021, 3, e0351.		13
167	Quantitative Assessment of the Physical Virus Titer and Purity by Ultrasensitive Flow Virometry. Angewandte Chemie, 2021, 133, 9437-9442.	1.6	3
168	Quantitative Assessment of the Physical Virus Titer and Purity by Ultrasensitive Flow Virometry. Angewandte Chemie - International Edition, 2021, 60, 9351-9356.	7.2	21
169	The relationship between the phageome and human health: are bacteriophages beneficial or harmful microbes?. Beneficial Microbes, 2021, 12, 107-120.	1.0	7

#	Article	IF	Citations
170	Formulations for Bacteriophage Therapy and the Potential Uses of Immobilization. Pharmaceuticals, 2021, 14, 359.	1.7	41
171	Viability of Bacteriophages in the Complex Hydrogel Wound Dressings in vitro. Sovremennye Tehnologii V Medicine, 2021, 13, 32.	0.4	5
172	Combatting intracellular pathogens using bacteriophage delivery. Critical Reviews in Microbiology, 2021, 47, 1-18.	2.7	13
173	Îµ2-Phages Are Naturally Bred and Have a Vastly Improved Host Range in Staphylococcus aureus over Wild Type Phages. Pharmaceuticals, 2021, 14, 325.	1.7	20
174	The Role of Bacterial Biofilms in Chronic Infectious Processes and the Search for Methods to Combat Them. Molecular Genetics, Microbiology and Virology, 2021, 36, 68-78.	0.0	3
175	Adsorption of bacteriophages on polypropylene labware affects the reproducibility of phage research. Scientific Reports, 2021, 11, 7387.	1.6	29
176	Phage Digestion of a Bacterial Capsule Imparts Resistance to Two Antibiotic Agents. Microorganisms, 2021, 9, 794.	1.6	3
177	Potential Use of Adjuvant Bacteriophage Therapy With Debridement, Antibiotics, and Implant Retention Surgery to Treat Chronic Prosthetic Joint Infections. Open Forum Infectious Diseases, 2021, 8, ofab277.	0.4	16
178	Therapeutic Efficacy of Bacteriophages. , 0, , .		2
179	Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections. Antibiotics, 2021, 10, 556.	1.5	11
180	Evaluation of the Stability of Bacteriophages in Different Solutions Suitable for the Production of Magistral Preparations in Belgium. Viruses, 2021, 13, 865.	1.5	34
181	Case Report: Arthroscopic â€œDebridement Antibiotics and Implant Retentionâ€•With Local Injection of Personalized Phage Therapy to Salvage a Relapsing Pseudomonas Aeruginosa Prosthetic Knee Infection. Frontiers in Medicine, 2021, 8, 569159.	1.2	35
182	Rekindling of a Masterful Precedent; Bacteriophage: Reappraisal and Future Pursuits. Frontiers in Cellular and Infection Microbiology, 2021, 11, 635597.	1.8	6
184	Phage vB_PaeS-PAJD-1 Rescues Murine Mastitis Infected With Multidrug-Resistant Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology, 2021, 11, 689770.	1.8	7
185	An Appraisal of Bacteriophage Isolation Techniques from Environment. Microbial Ecology, 2022, 83, 519-535.	1.4	7
186	Strong Antimicrobial and Healing Effects of Beta-Acids from Hops in Methicillin-Resistant Staphylococcus aureus-Infected External Wounds In Vivo. Antibiotics, 2021, 10, 708.	1.5	4
187	Bacteriophage Therapy for Critical and High-Priority Antibiotic-Resistant Bacteria and Phage Cocktail-Antibiotic Formulation Perspective. Food and Environmental Virology, 2021, 13, 433-446.	1.5	8
188	Development of thermosensitive hydrogel wound dressing containing Acinetobacter baumannii phage against wound infections. International Journal of Pharmaceutics, 2021, 602, 120508.	2.6	27

#	Article	IF	Citations
189	Goldâ€"Polyoxoborates Nanocomposite Prohibits Adsorption of Bacteriophages on Inner Surfaces of Polypropylene Labware and Protects Samples from Bacterial and Yeast Infections. Viruses, 2021, 13, 1206.	1.5	5
190	Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2053-2068.	1.3	44
191	Different Infection Profiles and Antimicrobial Resistance Patterns Between Burn ICU and Common Wards. Frontiers in Cellular and Infection Microbiology, 2021, 11, 681731.	1.8	13
192	Possibilities and Prospects of Application of Bacteriophages in the Treatment of Chronic Soft Tissue Wounds. Journal of Experimental and Clinical Surgery, 2021, 14, 168-174.	0.1	1
193	The Antibacterial Effect of Bacteriophage-Like Gold Nanoparticles. Nano, 2021, 16, 2150075.	0.5	1
194	The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies. Viruses, 2021, 13, 1268.	1.5	103
195	Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens. Antibiotics, 2021, 10, 672.	1.5	30
196	Evolutionary biology and development model of medicines: A necessary â€˜pas de deuxâ€™ for future successful bacteriophage therapy. Journal of Evolutionary Biology, 2021, 34, 1855-1866.	0.8	6
197	Manufacturing of bacteriophages for therapeutic applications. Biotechnology Advances, 2021, 49, 107758.	6.0	15
199	How to Train Your Phage: The Recent Efforts in Phage Training. Biologics, 2021, 1, 70-88.	2.3	21
200	Characterization of an Enterococcus faecalis Bacteriophage vB_EfaM_LG1 and Its Synergistic Effect With Antibiotic. Frontiers in Cellular and Infection Microbiology, 2021, 11, 698807.	1.8	6
201	Bacteriophages as tools for biofilm biocontrol in different fields. Biofouling, 2021, 37, 689-709.	0.8	4
202	Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nature Medicine, 2021, 27, 1357-1361.	15.2	94
203	Alternatives to Conventional Antibiotic Therapy: Potential Therapeutic Strategies of Combating Antimicrobial-Resistance and Biofilm-Related Infections. Molecular Biotechnology, 2021, 63, 1103-1124.	1.3	22
204	Recent progress toward the implementation of phage therapy in Western medicine. FEMS Microbiology Reviews, 2022, 46, .	3.9	50
205	The Future of Bacteriophage Therapy Will Promote Antimicrobial Susceptibility. MSystems, 2021, 6, e0021821.	1.7	5
206	Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections. Antibiotics, 2021, 10, 1030.	1.5	8
207	In vitro efficiency evaluation of phage cocktail for biocontrol of Salmonella spp. in food products. Archives of Microbiology, 2021, 203, 5445-5452.	1.0	6

#	Article	IF	Citations
208	A Rapid Method for Performing a Multivariate Optimization of Phage Production Using the RCCD Approach. Pathogens, 2021, 10, 1100.	1.2	2
209	Phage Therapy for Antibiotic-Resistant Bacterial Infections. Annual Review of Medicine, 2022, 73, 197-211.	5.0	182
210	Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections. Viruses, 2021, 13, 1809.	1.5	15
211	Lytic Bacteriophages Against Bacterial Biofilms Formed by Multidrug-Resistant Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus Isolated from Burn Wounds. Phage, 2021, 2, 120-130.	0.8	7
212	Use of Recombinant Endolysin to Improve Accuracy of Group B Streptococcus Tests. Microbiology Spectrum, 2021, 9, e0007721.	1.2	2
213	A commentary on the development of engineered phage as therapeutics. Drug Discovery Today, 2021, 26, 2095-2098.	3.2	9
214	The Role of Phage Therapy in Burn Wound Infections Management: Advantages and Pitfalls. Journal of Burn Care and Research, 2022, 43, 336-342.	0.2	11
215	Mechanisms and clinical importance of bacteriophage resistance. FEMS Microbiology Reviews, 2022, 46, .	3.9	92
216	Biomaterial-based antimicrobial therapies for the treatment of bacterial infections. Nature Reviews Materials, 2022, 7, 39-54.	23.3	184
217	Formulation strategies for bacteriophages to target intracellular bacterial pathogens. Advanced Drug Delivery Reviews, 2021, 176, 113864.	6.6	31
218	Phage Therapy Experience at the Eliava Phage Therapy Center: Three Cases of Bacterial Persistence. Viruses, 2021, 13, 1901.	1.5	21
219	Clinical Phage Microbiology: a suggested framework and recommendations for the in-vitro matching steps of phage therapy. Lancet Microbe, The, 2021, 2, e555-e563.	3.4	39
221	Regulatory Aspects of the Therapeutic Use of Bacteriophages: Europe. , 2021, , 1165-1177.		1
222	Production of Phage Therapeutics and Formulations: Innovative Approaches. , 2019, , 3-41.		2
223	Phage Therapy of Infectious Biofilms: Challenges and Strategies. , 2019, , 295-313.		6
224	Phage Therapy in Europe: Regulatory and Intellectual Property Protection Issues. , 2019, , 363-377.		2
225	How to Achieve a Good Phage Therapy Clinical Trial?. , 2019, , 147-168.		4
226	Phagetherapy: Clinical ApplicationsÂâ€“ Critical Appraisal of Randomized Controlled Trials. , 2020, , 371-383.		1

#	Article	IF	Citations
227	Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Communications, 2020, 6, .	4.7	158
228	The future of phage clinical trials in Australia. Microbiology Australia, 2019, 40, 16.	0.1	4
229	Bacteriophage therapy for severe infections. Microbiology Australia, 2019, 40, 20.	0.1	3
230	Bacteriophages of spp., their diversity and potential therapeutic uses. Journal of Medical Microbiology, 2020, 69, 176-194.	0.7	49
233	Antibiotic resistance and persistenceâ€"Implications for human health and treatment perspectives. EMBO Reports, 2020, 21, e51034.	2.0	228
234	Application of Phagotherapy in the Treatment of Burn Patients (Review). Sovremennye Tehnologii V Medicine, 2020, 12, 95.	0.4	4
235	Engineering a Model to Study Viral Infections: Bioprinting, Microfluidics, and Organoids to Defeat Coronavirus Disease 2019 (COVID-19). International Journal of Bioprinting, 2020, 6, 302.	1.7	38
236	The use of bacteriophages for prevention of infections in the surgical area at free skin grafting. MediAl, 2019, , 19-21.	0.3	2
237	The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients?. Cancers, 2021, 13, 13.	1.7	21
238	Bacteriophage Treatment: Critical Evaluation of Its Application on World Health Organization Priority Pathogens. Viruses, 2021, 13, 51.	1.5	23
239	An exegesis of bacteriophage therapy: An emerging player in the fight against anti-microbial resistance. AIMS Microbiology, 2020, 6, 204-230.	1.0	19
240	Nanotechnology Based Approaches in Phage Therapy: Overcoming the Pharmacological Barriers. Frontiers in Pharmacology, 2021, 12, 699054.	1.6	25
241	Modern Tendencies of the Use and Development of Drugs of Bacteriophages. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 351-360.	0.2	3
242	Engineered Bacteriophage as a Delivery Vehicle for Antibacterial Protein, SASP. Pharmaceuticals, 2021, 14, 1038.	1.7	13
243	Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists. Infectious Diseases and Therapy, 2021, 10, 2177-2202.	1.8	27
244	Individual bacteria in structured environments rely on phenotypic resistance to phage. PLoS Biology, 2021, 19, e3001406.	2.6	26
245	Evaluation of Phage Therapy for Pulmonary Infection of Mouse by Liquid Aerosol-Exposure Pseudomonas aeruginosa. Infection and Drug Resistance, 2021, Volume 14, 4457-4469.	1.1	4
246	Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth. Pharmaceuticals, 2021, 14, 1019.	1.7	72

#	Article	IF	Citations
247	Phage Pharmacokinetics: Relationship with Administration Route. , 2019, , 43-57.		5
254	Efficiency of phage therapy in humans: systematic review. Jurnal Infektologii, 2019, 11, 19-30.	0.1	3
255	Phage therapy in osteoarticular infections in the era of antibiotic resistance bacteria. Journal of Education, Health and Sport, 2020, 10, 119.	0.0	0
257	Bacteriophage as a Therapeutic Agent to Combat Bacterial Infection: A Journey from History to Application. , 2020, , 347-370.		0
258	Bacteriophage as Biocontrol Agents. , 2020, , 1-16.		0
259	Patient perceptions of phage therapy for diabetic foot infection. PLoS ONE, 2020, 15, e0243947.	1.1	11
260	HSF1 Alleviates Microthrombosis and Multiple Organ Dysfunction in Mice with Sepsis by Upregulating the Transcription of Tissue-Type Plasminogen Activator. Thrombosis and Haemostasis, 2021, 121, 1066-1078.	1.8	8
261	Phages as Therapy or â€œDietary Supplementsâ€•Against Multiresistant Bacteria?. , 2020, , 293-307.		0
262	Selection of Disease Targets for Phage Therapy. , 2020, , 1-22.		0
263	Regulatory Aspects of the Therapeutic Use of Bacteriophages: Europe. , 2020, , 1-13.		0
264	Phage Therapy in Cystic Fibrosis. Challenges and Perspectives. , 2020, , 403-461.		0
265	Suche nach neuen Antibiotika und Therapiealternativen. , 2020, , 221-223.		0
266	Management of uncomplicated recurrent urinary tract infections. BJU International, 2022, 129, 668-678.	1.3	15
267	Suche nach neuen Antibiotika und Therapiealternativen. , 2021, , 253-255.		0
268	Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?. Pharmaceuticals, 2021, 14, 1157.	1.7	32
269	Renaissance for Phage-Based Bacterial Control. Environmental Science & Technology, 2022, 56, 4691-4701.	4.6	15
270	Uses of Bacteriophages as Bacterial Control Tools and Environmental Safety Indicators. Frontiers in Microbiology, 2021, 12, 793135.	1.5	14
271	Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy. International Journal of Antimicrobial Agents, 2022, 59, 106475.	1.1	13

#	Article	IF	Citations
272	Friends or Foes? Rapid Determination of Dissimilar Colistin and Ciprofloxacin Antagonism of Pseudomonas aeruginosa Phages. Pharmaceuticals, 2021, 14, 1162.	1.7	15
273	Polymer-Mediated Cryopreservation of Bacteriophages. Biomacromolecules, 2021, 22, 5281-5289.	2.6	8
274	Phage therapeutics: from promises to practices and prospectives. Applied Microbiology and Biotechnology, 2021, 105, 9047-9067.	1.7	19
275	Bacteriophages for the Treatment of Graft Infections in Cardiovascular Medicine. Antibiotics, 2021, 10, 1446.	1.5	2
276	Survival Comes at a Cost: A Coevolution of Phage and Its Host Leads to Phage Resistance and Antibiotic Sensitivity of Pseudomonas aeruginosa Multidrug Resistant Strains. Frontiers in Microbiology, 2021, 12, 783722.	1.5	12
277	Shopping for phages? Unpacking design rules for therapeutic phage cocktails. Current Opinion in Virology, 2022, 52, 236-243.	2.6	15
278	Engineering therapeutic phages for enhanced antibacterial efficacy. Current Opinion in Virology, 2022, 52, 182-191.	2.6	36
279	Phage Therapy. WikiJournal of Medicine, 2021, 8, 4.	1.0	1
280	Limb Salvage through Intermediary Wound Coverage with Acellular Dermal Matrix Template after Persistent Pseudomonas Aeruginosa Infection in a Burn Patient. European Journal of Burn Care, 2022, 3, 27-33.	0.4	2
281	Bacteriophageâ€Loaded Poly(lacticâ€coâ€glycolic acid) Microparticles Mitigate Staphylococcus aureus Infection and Cocultures of Staphylococcus aureus and Pseudomonas aeruginosa. Advanced Healthcare Materials, 2022, 11, e2102539.	3.9	8
282	Characterization andin vitrotesting of newly isolated lytic bacteriophages for theÂbiocontrol ofPseudomonas aeruginosa. Future Microbiology, 2022, 17, 111-141.	1.0	7
283	Phage Therapy as an Alternative Treatment in the Fight Against AMR: Real-World Problems and Possible Futures. , 2022, , 357-374.		2
284	Phage therapy of wound-associated infections. Folia Microbiologica, 2022, 67, 193-201.	1.1	15
285	Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0207121.	1.4	151
286	Prospects of bacteriophage collections in disinfectant applications. Veterinary World, 2022, 15, 220-231.	0.7	1
287	Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically Against Staphylococcus aureus Experimental Infective Endocarditis. Journal of the American Heart Association, 2022, 11, e023080.	1.6	11
288	The potential of bacteriophage therapy in the treatment of paediatric respiratory infections. Paediatric Respiratory Reviews, 2022, , .	1.2	2
289	PhageLeads: Rapid Assessment of Phage Therapeutic Suitability Using an Ensemble Machine Learning Approach. Viruses, 2022, 14, 342.	1.5	31

#	Article	IF	Citations
290	Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics. Antibiotics, 2022, 11, 200.	1.5	101
291	Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa. Infectious Diseases and Therapy, 2022, 11, 661-682.	1.8	80
292	Practical Assessment of an Interdisciplinary Bacteriophage Delivery Pipeline for Personalized Therapy of Gram-Negative Bacterial Infections. Pharmaceuticals, 2022, 15, 186.	1.7	8
293	Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection. Viruses, 2021, 13, 2414.	1.5	16
294	T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target Specificity. Advanced Science, 2022, 9, e2103645.	5.6	27
295	Risk of Bacteriophage Therapeutics to Transfer Genetic Material and Contain Contaminants Beyond Endotoxins with Clinically Relevant Mitigation Strategies. Infection and Drug Resistance, 2021, Volume 14, 5629-5637.	1.1	11
296	Antibiotic Resistance: One Health One World Outlook. Frontiers in Cellular and Infection Microbiology, 2021, 11, 771510.	1.8	189
297	Assessment of Staphylococcal Clinical Isolates from Periprosthetic Joint Infections for Potential Bacteriophage Therapy. Journal of Bone and Joint Surgery - Series A, 2022, 104, 693-699.	1.4	12
298	Diversity of Pseudomonas aeruginosa Temperate Phages. MSphere, 2022, 7, e0101521.	1.3	16
299	Phage-bacterial evolutionary interactions: experimental models and complications. Critical Reviews in Microbiology, 2023, 49, 283-296.	2.7	2
300	Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infectious Diseases, The, 2022, 22, e208-e220.	4.6	125
301	Novel Diagnostic Technologies and Therapeutic Approaches Targeting Chronic Wound Biofilms and Microbiota. Current Dermatology Reports, 2022, 11, 60-72.	1.1	3
302	inPhocus: Current State and Challenges of Phage Research in Singapore. Phage, 2022, 3, 6-11.	0.8	0
303	Essential Topics for the Regulatory Consideration of Phages as Clinically Valuable Therapeutic Agents: A Perspective from Spain. Microorganisms, 2022, 10, 717.	1.6	12
304	Human Plasma Significantly Reduces Bacteriophage Infectivity Against Staphylococcus aureus Clinical Isolates. Cureus, 2022, 14, e23777.	0.2	5
305	Protein Cages: From Fundamentals to Advanced Applications. Chemical Reviews, 2022, 122, 9145-9197.	23.0	54
306	A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens. IScience, 2022, 25, 104121.	1.9	12
307	Combating antimicrobial resistance: an evidence-based overview of bacteriophage therapy. Postgraduate Medical Journal, 2022, , postgradmedj-2022-141546.	0.9	1

#	Article	IF	Citations
308	Mitigation of evolved bacterial resistance to phage therapy. Current Opinion in Virology, 2022, 53, 101201.	2.6	27
309	Conventional Treatment of Burn Wound Infections versus Phage Therapy. Iranian Journal of Medical Microbiology, 2022, 16, 186-196.	0.1	3
310	Nanosilver Dressing in Treating Deep II Degree Burn Wound Infection in Patients with Clinical Studies. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-7.	0.7	4
311	The History and Applications of Phage Therapy in Pseudomonas aeruginosa. Microbiology Research, 2022, 13, 14-37.	0.8	7
312	Potential Solutions Using Bacteriophages against Antimicrobial Resistant Bacteria. Antibiotics, 2021, 10, 1496.	1.5	4
313	Preclinical Assessment of Bacteriophage Therapy against Experimental Acinetobacter baumannii Lung Infection. Viruses, 2022, 14, 33.	1.5	4
314	Phage-Choline Kinase Inhibitor Combination to Control Pseudomonas aeruginosa: A Promising Combo. Mini-Reviews in Medicinal Chemistry, 2021, 21, .	1.1	0
315	Phage Therapy in the Era of Multidrug Resistance in Bacteria: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 4577.	1.8	15
321	Bacteriophages and related endolysins for reduction of microorganisms in the human body - a systematic review.. GMS Hygiene and Infection Control, 2022, 17, Doc01.	0.2	1
322	Ruminal Phages â€“ A Review. Frontiers in Microbiology, 2021, 12, 763416.	1.5	11
323	Role of Systemic Antibiotic Prophylaxis and Burn Dressings in Preventing Invasive Burn Infections â€“ A Systematic Review. Journal of Medical Evidence, 2022, 3, 28.	0.2	0
324	Can Bacteriophages Replace Antibiotics?. Antibiotics, 2022, 11, 575.	1.5	4
325	Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection. Antibiotics, 2022, 11, 616.	1.5	13
326	Antibiofilm Efficacy of the Pseudomonas aeruginosaÂPbunavirus vB_PaeM-SMS29 Loaded onto Dissolving Polyvinyl Alcohol Microneedles. Viruses, 2022, 14, 964.	1.5	7
327	Prevention of Acinetobacter baumannii outbreak in a military burn center. Burns, 2022, , .	1.1	0
328	Recent advances in bacteriophage-based therapeutics: Insight into the post-antibiotic era. Acta Pharmaceutica Sinica B, 2022, 12, 4348-4364.	5.7	36
329	Combination of inÂvivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy. Cell Reports, 2022, 39, 110825.	2.9	19
330	Isolation and Analysis of the Biological Characteristics of a Novel Bacteriophage vB_SauP_P992 Against Staphylococcus aureus. Jundishapur Journal of Microbiology, 2022, 15, .	0.2	1

#	Article	IF	Citations
331	Paving the way for phage therapy using novel drug delivery approaches. Journal of Controlled Release, 2022, 347, 414-424.	4.8	19
332	Ultrafast and Multiplexed Bacteriophage Susceptibility Testing by Surface Plasmon Resonance and Phase Imaging of Immobilized Phage Microarrays. Chemosensors, 2022, 10, 192.	1.8	8
333	Pharmacokinetic Assessment of Staphylococcal Phage K Following Parenteral and Intra-articular Administration in Rabbits. Frontiers in Pharmacology, 2022, 13, .	1.6	1
334	Construction and Characterization of T7 Bacteriophages Harboring Apidaecin-Derived Sequences. Current Issues in Molecular Biology, 2022, 44, 2554-2568.	1.0	0
335	Topical liquid formulation of bacteriophages for metered-dose spray delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 177, 1-8.	2.0	4
336	Bacteriophage: A potential biocontrol agent. , 2022, , 163-174.		0
337	Resistance Is Not Futile: The Role of Quorum Sensing Plasticity in Pseudomonas aeruginosa Infections and Its Link to Intrinsic Mechanisms of Antibiotic Resistance. Microorganisms, 2022, 10, 1247.	1.6	12
338	Phage Therapy in Israel, Past, Present, and Future. Phage, 2022, 3, 85-94.	0.8	2
339	Isolation of a lytic bacteriophage against extensively drugâ€resistant Acinetobacter baumannii infections and its dramatic effect in rat model of burn infection. Journal of Clinical Laboratory Analysis, 0, , .	0.9	7
340	Bactericidal Synergism between Phage YC#06 and Antibiotics: a Combination Strategy to Target Multidrug-Resistant Acinetobacter baumannii In Vitro and In Vivo. Microbiology Spectrum, 2022, 10, .	1.2	14
341	Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. Clinical Infectious Diseases, 2023, 76, 103-112.	2.9	109
342	Bacteriophage Therapy for Staphylococcus Aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	27
343	Phage therapy in the treatment of combat trauma. Wounds and Wound Infections the Prof B M Kostyuchenok Journal, 2022, 9, 6-11.	0.1	0
344	Mutualistic interplay between bacteriophages and bacteria in the human gut. Nature Reviews Microbiology, 2022, 20, 737-749.	13.6	47
345	Bacteriophage-Resistant Mutant of Enterococcus faecalis Is Impaired in Biofilm Formation. Frontiers in Microbiology, 0, 13, .	1.5	6
346	Phage Products for Fighting Antimicrobial Resistance. Microorganisms, 2022, 10, 1324.	1.6	17
347	What Is New in the Antiâ€“Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	16
348	Cell-free production of personalized therapeutic phages targeting multidrug-resistant bacteria. Cell Chemical Biology, 2022, 29, 1434-1445.e7.	2.5	23

#	Article	IF	Citations
349	Increased Innate Immune Susceptibility in Hyperpigmented Bacteriophage-Resistant Mutants of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 0, , .	1.4	3
350	Membrane lipid renovation in Pseudomonas aeruginosa â€•implications for phage therapy?. Environmental Microbiology, 2022, 24, 4533-4546.	1.8	2
351	Preliminary Reproducibility Evaluation of a Phage Susceptibility Testing Method Using a Collection of Escherichia coli and Staphylococcus aureus Phages. journal of applied laboratory medicine, The, 2022, 7, 1468-1475.	0.6	4
352	Bacteriophage and Bacterial Susceptibility, Resistance, and Tolerance to Antibiotics. Pharmaceutics, 2022, 14, 1425.	2.0	15
353	Nanocapping-enabled charge reversal generates cell-enterable endosomal-escapable bacteriophages for intracellular pathogen inhibition. Science Advances, 2022, 8, .	4.7	14
354	Characterization of Pseudomonas aeruginosa Bacteriophage L5 Which Requires Type IV Pili for Infection. Frontiers in Microbiology, 0, 13, .	1.5	2
355	Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nature Communications, 2022, 13, .	5.8	42
356	Phage Therapy: Challenges and Opportunities. Fine Focus, 2022, 8, 12-35.	0.2	0
357	Antibiotic Resistance and Mechanisms of Pathogenic Bacteria in Tubo-Ovarian Abscess. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	0
358	Phascinating Phages. Microorganisms, 2022, 10, 1365.	1.6	1
359	Antibacterial efficacy of lytic phages against multidrug-resistant Pseudomonas aeruginosa infections in bacteraemia mice models. BMC Microbiology, 2022, 22, .	1.3	6
360	Phage Therapy Starts Realizing Its Long-Deferred Potential. Genetic Engineering and Biotechnology News, 2022, 42, 20-22, 24.	0.1	0
363	The resurgence of phage-based therapy in the era of increasing antibiotic resistance: From research progress to challenges and prospects. Microbiological Research, 2022, 264, 127155.	2.5	21
364	Enhancing the Stability of Bacteriophages Using Physical, Chemical, and Nano-Based Approaches: A Review. Pharmaceutics, 2022, 14, 1936.	2.0	10
366	Improved antibacterial activity by incorporation of silver sulfadiazine on Nanoporous Cu-BTC Metal-organic-framework. Inorganica Chimica Acta, 2022, 543, 121182.	1.2	1
367	Bacteriophages for the Treatment of Biofilm-Associated Infections. Springer Series on Biofilms, 2022, , 181-199.	0.0	0
368	Quest for Alternatives to Antibiotics: An Urgent Need of the Twenty-First Century. , 2022, , 3-32.		0
369	Metagenome data-based phage therapy for intestinal bacteria-mediated diseases. Bioscience of Microbiota, Food and Health, 2022, , .	0.8	0

#	Article	IF	Citations
370	Intestinal phages interact with bacteria and are involved in human diseases. Gut Microbes, 2022, 14, .	4.3	26
371	Editing of Phage Genomesâ€”Recombineering-assisted SpCas9 Modification of Model Coliphages T7, T5, and T3. Molecular Biology, 2022, 56, 801-815.	0.4	5
372	Reassessment of Historical Clinical Trials Supports the Effectiveness of Phage Therapy. Clinical Microbiology Reviews, 2022, 35, .	5.7	14
373	Multifunctional DNA Hydrogel Enhances Stemness of Adiposeâ€Derived Stem Cells to Activate Immune Pathways for Guidance Burn Wound Regeneration. Advanced Functional Materials, 2022, 32, .	7.8	25
374	Novel technologies to characterize and engineer the microbiome in inflammatory bowel disease. Gut Microbes, 2022, 14, .	4.3	4
375	Determination of phage susceptibility as a clinical diagnostic tool: A routine perspective. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	12
376	Phage-based therapy: promising applicability in the control of oral dysbiosis and respiratory infections. Future Microbiology, 0, , 00-00.	1.0	0
377	Microbiome-phage interactions in inflammatory bowel disease. Clinical Microbiology and Infection, 2023, 29, 682-688.	2.8	10
379	Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations. European Respiratory Review, 2022, 31, 220121.	3.0	14
380	Biofilm-Associated Infections in Chronic Wounds and Their Management. Advances in Experimental Medicine and Biology, 2022, , 55-75.	0.8	2
381	The Safety and Efficacy of Phage Therapy: A Systematic Review of Clinical and Safety Trials. Antibiotics, 2022, 11, 1340.	1.5	30
383	Isolation and Characterization of Lytic Pseudomonas aeruginosa Bacteriophages Isolated from Sewage Samples from Tunisia. Viruses, 2022, 14, 2339.	1.5	4
384	A Combination of Virulent and Non-Productive Phages Synergizes the Immune System against Salmonella Typhimurium Systemic Infection. International Journal of Molecular Sciences, 2022, 23, 12830.	1.8	3
386	Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans. Pathogens and Immunity, 2022, 7, 1-45.	1.4	8
387	Basic Guidelines for Bacteriophage Isolation and Characterization. Recent Patents on Biotechnology, 2023, 17, 312-331.	0.4	2
388	Therapeutic effects of oral administration of lytic Salmonella phages in a mouse model of non-typhoidal salmonellosis. Frontiers in Microbiology, 0, 13, .	1.5	4
389	Isolation and characterization of novel Fusobacterium nucleatum bacteriophages. Frontiers in Microbiology, 0, 13, .	1.5	5
390	Efficacy of phage therapy in preclinical models of bacterial infection: a systematic review and meta-analysis. Lancet Microbe, The, 2022, 3, e956-e968.	3.4	8

#	Article	IF	Citations
391	A perfect fit: Bacteriophage receptor-binding proteins for diagnostic and therapeutic applications. Current Opinion in Microbiology, 2023, 71, 102240.	2.3	16
392	Tracking the phage trends: A comprehensive review of applications in therapy and food production. Frontiers in Microbiology, 0, 13, .	1.5	0
393	Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial. BMJ Open, 2022, 12, e065401.	0.8	15
394	In Vitro and Pre-Clinical Evaluation of Locally Isolated Phages, vB_Pae_SMP1 and vB_Pae_SMP5, Formulated as Hydrogels against Carbapenem-Resistant Pseudomonas aeruginosa. Viruses, 2022, 14, 2760.	1.5	4
395	Les virus au service de la santÃ©Â: lesÂbactÃ©riophages. Medecine/Sciences, 2022, 38, 1043-1051.	0.0	0
396	Treatment of Complex Wounds with NovoSorbÂ® Biodegradable Temporising Matrix (BTM)â€"A Retrospective Analysis of Clinical Outcomes. Journal of Personalized Medicine, 2022, 12, 2002.	1.1	4
397	Rapid hydrogel-based phage susceptibility test for pathogenic bacteria. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	4
398	Alternatives Therapeutic Approaches to Conventional Antibiotics: Advantages, Limitations and Potential Application in Medicine. Antibiotics, 2022, 11, 1826.	1.5	10
399	Phage Therapy as a Protective Tool Against Pathogenic Bacteria: How Far We Are?. Current Pharmaceutical Biotechnology, 2023, 24, 1277-1290.	0.9	5
400	Biological properties of Staphylococcus virus Î¦SA012 for phage therapy. Scientific Reports, 2022, 12, .	1.6	5
401	Global trends and hotspots of phage therapy for bacterial infection: A bibliometric visualized analysis from 2001 to 2021. Frontiers in Microbiology, 0, 13, .	1.5	12
402	Characterisation and sequencing of the novel phage Abp95, which is effective against multi-genotypes of carbapenem-resistant Acinetobacter baumannii. Scientific Reports, 2023, 13, .	1.6	4
403	Phage therapy: From biological mechanisms to future directions. Cell, 2023, 186, 17-31.	13.5	125
404	The dynamic interplay of bacteriophage, bacteria and the mammalian host during phage therapy. IScience, 2023, 26, 106004.	1.9	12
405	Bacteriophage therapy for human musculoskeletal and skin/soft tissue infections. Clinical Microbiology and Infection, 2023, 29, 695-701.	2.8	7
406	Current Promising Strategies against Antibiotic-Resistant Bacterial Infections. Antibiotics, 2023, 12, 67.	1.5	16
407	Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial. Trials, 2022, 23, .	0.7	16
408	Advances in the field of phage-based therapy with special emphasis on computational resources. Briefings in Bioinformatics, 2023, 24, .	3.2	3

#	Article	IF	Citations
409	Phages against killer superbugs: An enticing strategy against antibiotics-resistant pathogens. Frontiers in Pharmacology, 0, 14, .	1.6	8
410	Current landscape on phage therapy in infections: time to leave it behind for good?. Clinical Microbiology and Infection, 2023, 29, 565-567.	2.8	2
411	Natural biopolymer scaffolds for bacteriophage delivery in the medical field. , 2023, , 769-793.		1
412	Antimicrobial Therapeutic Strategies For Enterococcus faecalis In Dental Infections - Past, Present and Future. Anti-Infective Agents, 2023, 21, .	0.1	0
413	Three Innovations of Next-Generation Antibiotics: Evolvability, Specificity, and Non-Immunogenicity. Antibiotics, 2023, 12, 204.	1.5	10
414	Antimicrobial Resistance and Recent Alternatives to Antibiotics for the Control of Bacterial Pathogens with an Emphasis on Foodborne Pathogens. Antibiotics, 2023, 12, 274.	1.5	21
415	Bacteriophages as Biotechnological Tools. Viruses, 2023, 15, 349.	1.5	13
416	Removal and control of biofilms in wounds. , 2023, , 275-289.		0
417	Repetitive Exposure to Bacteriophage Cocktails against Pseudomonas aeruginosa or Escherichia coli Provokes Marginal Humoral Immunity in NaÃ¯ve Mice. Viruses, 2023, 15, 387.	1.5	1
418	Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation. Clinical Microbiology and Infection, 2023, 29, 702-709.	2.8	12
419	Composition of Bacteriophages for Therapeutic and Prophylactic Use in Monkeys. Bulletin of Experimental Biology and Medicine, 2023, 174, 376-379.	0.3	0
420	Phages for treatment Pseudomonas aeruginosa infection. Progress in Molecular Biology and Translational Science, 2023, , 1-19.	0.9	0
421	Phage for regenerative medicine and cosmetics. Progress in Molecular Biology and Translational Science, 2023, , 241-259.	0.9	0
422	The Future of Clinical Phage Therapy in the United Kingdom. Viruses, 2023, 15, 721.	1.5	15
423	Burn wound infections microbiome and novel approaches using therapeutic microorganisms in burn wound infection control. Advanced Drug Delivery Reviews, 2023, 196, 114769.	6.6	5
424	Development and Evaluation of Bacteriophage Cocktail to Eradicate Biofilms Formed by an Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa. Viruses, 2023, 15, 427.	1.5	2
425	Complete Genome Sequence of the Lysogenic Pseudomonas Bacteriophage Fyn8. Microbiology Resource Announcements, 2023, 12, .	0.3	0
426	Role of Bacteriophages as Non-traditional Approaches to Combat Multidrug Resistance. , 2023, , 141-177.		0

#	Article	IF	Citations
427	Bioengineered materials with selective antimicrobial toxicity in biomedicine. Military Medical Research, 2023, 10, .	1.9	2
428	The spread of antibiotic resistance to humans and potential protection strategies. Ecotoxicology and Environmental Safety, 2023, 254, 114734.	2.9	27
429	The applications of animal models in phage therapy: An update. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	7
430	The Influence of Bacteriophages on the Metabolic Condition of Human Fibroblasts in Light of the Safety of Phage Therapy in Staphylococcal Skin Infections. International Journal of Molecular Sciences, 2023, 24, 5961.	1.8	1
431	Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials. Microorganisms, 2023, 11, 916.	1.6	6
432	Non-Antibiotic Approaches to Infection that Preserve the Microbiome in Critically Ill Patients. Surgical Infections, 2023, 24, 284-291.	0.7	0
433	Host-phage interactions and modeling for therapy. Progress in Molecular Biology and Translational Science, 2023, , 127-158.	0.9	0
434	Phage therapy of antibiotic-resistant strains of Klebsiella pneumoniae, opportunities and challenges from the past to the future. Folia Microbiologica, 0, , .	1.1	1
435	A Century of Clinical Use of Phages: A Literature Review. Antibiotics, 2023, 12, 751.	1.5	9
436	Current Clinical Landscape and Global Potential of Bacteriophage Therapy. Viruses, 2023, 15, 1020.	1.5	19
437	Acinetobacter baumannii Bacteriophage: Progress in Isolation, Genome Sequencing, Preclinical Research, and Clinical Application. Current Microbiology, 2023, 80, .	1.0	3
442	Microbiome subtractive therapy for health benefits. , 2023, , 63-94.		0
451	Phages for treatment of Staphylococcus aureus infection. Progress in Molecular Biology and Translational Science, 2023, , .	0.9	0
452	Phage and phage cocktails formulations. Progress in Molecular Biology and Translational Science, 2023, , 159-169.	0.9	1
472	Nanotechnology for bacteriophages, bacteriophages for nanotechnology. , 2023, , 243-271.		0
477	Phage therapy in the battle towards antibiotic resistance. , 2023, , .		0
479	Bacteriophage therapy: are we running before we have learned to walk?. European Journal of Clinical Microbiology and Infectious Diseases, 2023, 42, 1281-1283.	1.3	0
480	Gram-Negative Infection. , 2023, , 69-102.		0

#	Article	IF	Citations
498	Alternative therapeutic strategies to treat antibiotic-resistant pathogens. Nature Reviews Microbiology, 0, , .	13.6	2
510	Bacteriophage Treatment of Infected Diabetic Foot Ulcers. Methods in Molecular Biology, 2024, , 197-205.	0.4	0
511	Bacteriophage Production in Compliance with Regulatory Requirements. Methods in Molecular Biology, 2024, , 89-115.	0.4	1
512	Rapid Bench to Bedside Therapeutic Bacteriophage Production. Methods in Molecular Biology, 2024, , 67-88.	0.4	0
514	The Potential of Bacteriophages in Treating Covid-19-Associated Secondary Infections. , 2023, , 547-579.		0
515	Reminiscing Phages in the Era of Superbugs. , 2023, , 537-546.		0
517	Use of phages as antimicrobial agents. , 2024, , 575-596.		0
520	Acinetobacter baumannii. , 2024, , 853-877.		0
521	Respiratory Delivery of Bacteriophages for the Treatment of Lung Infections. AAPS Introductions in the Pharmaceutical Sciences, 2023, , 173-191.	0.1	0
530	Phage therapy as a glimmer of hope in the fight against the recurrence or emergence of surgical site bacterial infections. Infection, 2024, 52, 385-402.	2.3	0